Published in Chest on September 01, 2012
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Correlation of regional emphysema and lung cancer: a lung tissue research consortium-based study. J Thorac Oncol (2014) 0.86
Prevention of exacerbations in patients with COPD and vitamin D deficiency through vitamin D supplementation (PRECOVID): a study protocol. BMC Pulm Med (2015) 0.79
Functional impact of sarcopenia in respiratory muscles. Respir Physiol Neurobiol (2015) 0.78
Older adults with chronic lung disease report less limitation compared with younger adults with similar lung function impairment. Ann Am Thorac Soc (2015) 0.77
The COPD Assessment Test as a Prognostic Marker in Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care (1996) 70.87
Standardisation of spirometry. Eur Respir J (2005) 48.20
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis (1992) 15.92
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes (2005) 2.42
Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax (1997) 2.32
Assessment of health-related quality of life in patients with interstitial lung disease. Chest (1999) 2.21
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 2.01
Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J (2009) 1.99
Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax (1996) 1.94
Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health Qual Life Outcomes (2011) 1.94
Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest (1995) 1.90
Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.59
A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest (1999) 1.53
Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med (2005) 1.51
Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J (2001) 1.50
Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes (2006) 1.49
Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J (2002) 1.48
Dyspnea and activity limitation in COPD: mechanical factors. COPD (2007) 1.23
Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med (2000) 1.23
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir Med (2007) 1.10
Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med (2004) 1.06
Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit (2002) 1.02
Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish Study. Int J Chron Obstruct Pulmon Dis (2008) 0.99
Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) (2006) 0.99
Gender influences Health-Related Quality of Life in IPF. Respir Med (2009) 0.92
Influence of respiratory function parameters on the quality of life of COPD patients. J Bras Pneumol (2009) 0.90
Factors determining the quality of life of patients with COPD in primary care. Ther Adv Respir Dis (2007) 0.88
Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease. J Rehabil Res Dev (2009) 0.87
Prediction of maximal exercise capacity in obstructive and restrictive pulmonary disease. Chest (1993) 0.86
Relationship between disease severity and quality of life in patients with chronic obstructive pulmonary disease. Braz J Med Biol Res (2008) 0.83
Dyspnea on exercise. Pathophysiologic mechanisms. Chest (1992) 0.77
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 17.08
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med (2005) 8.86
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med (2009) 5.90
Pneumocystis pneumonia. N Engl J Med (2004) 5.86
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med (2007) 4.40
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med (2008) 3.94
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA (2012) 3.40
Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med (2011) 3.33
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 3.24
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Diffuse alveolar hemorrhage. Chest (2010) 2.90
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 2.82
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One (2008) 2.67
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med (2009) 2.63
Maternal vitamin A supplementation and lung function in offspring. N Engl J Med (2010) 2.61
A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat Immunol (2013) 2.60
Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med (2010) 2.60
Calcium deposition with or without bone formation in the lung. Am J Respir Crit Care Med (2002) 2.57
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol (2007) 2.50
Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A (2004) 2.42
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2007) 2.19
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
The relationship between pulmonary emphysema and kidney function in smokers. Chest (2012) 2.13
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Automated lung segmentation in X-ray computed tomography: development and evaluation of a heuristic threshold-based scheme. Acad Radiol (2003) 2.10
Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J (2005) 2.09
Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.09
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax (2007) 2.05
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 2.05
Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med (2004) 2.05
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med (2003) 2.03
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99
Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis (2002) 1.98
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98
Significance of the microbiome in obstructive lung disease. Thorax (2012) 1.97
Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94
Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.94
Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol (2005) 1.93
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Body mass index and the risk of COPD. Chest (2002) 1.91
An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.90